Screener
Gilead Sciences GILD Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| AmBisome | $110M-14.7% | $138M-0.7% | $118M+8.3% | $123M-5.4% | $129M-14.6% | |
| Biktarvy | $3.77B+6.9% | $3.36B+6.7% | $3.97B+5.1% | $3.69B+6.2% | $3.53B+9.2% | |
| Descovy | $967M+48.1% | $807M+37.7% | $819M+32.7% | $701M+19.6% | $653M+34.6% | |
| Genvoya | $289M-23.3% | $264M-27.5% | $380M-19.1% | $377M-16.0% | $377M-14.3% | |
| Livdelzi | $167M+114% | $133M+233% | —— | —— | $78M— | |
| Odefsey | $239M-19.8% | $221M-21.4% | $310M-7.7% | $277M-15.0% | $298M-5.4% | |
| Other HIV | $56M-39.1% | $73M-19.8% | $190M+69.6% | $112M+12.0% | $92M-12.4% | |
| Other Liver Disease | $118M-4.1% | $114M-5.8% | $281M+116% | $231M+99.1% | $123M+8.8% | |
| Other | $51M-30.1% | $58M-17.1% | $86M+14.7% | $61M-14.1% | $73M-43.8% | |
| Royalty, contract and other revenues | $176M+552% | $14M-74.1% | $22M-33.3% | $424M+1,313% | $27M-34.1% | |
| Sofosbuvir/Velpatasvir | $303M-11.4% | $283M-18.2% | $276M-16.4% | $309M-19.7% | $342M-28.2% | |
| Symtuza - Revenue share | $138M+11.3% | $138M+21.1% | $133M-7.6% | $124M-10.8% | $124M-26.2% | |
| Tecartus | $70M-23.9% | $75M-3.8% | $90M-8.2% | $83M-15.3% | $92M-14.0% | |
| Trodelvy | $457M+25.5% | $402M+37.2% | $384M+8.2% | $357M+7.5% | $364M+13.8% | |
| Veklury | $23M-81.0% | $144M-52.3% | $211M-37.6% | $277M-60.0% | $121M-43.5% | |
| Vemlidy | $289M+14.7% | $237M-6.0% | $287M+10.4% | $280M+20.7% | $252M+3.7% | |
| Yescarta | $346M-12.0% | $332M-14.0% | $368M-5.4% | $349M-9.8% | $393M-5.1% | |
| Yeztugo | $232M+1,447% | $166M— | —— | —— | $15M— | |
| Total revenues by Geography | ||||||
| Europe | $1.32B+11.4% | $1.14B+5.5% | $1.24B+5.2% | $1.56B+33.2% | $1.19B+4.9% | |
| Rest of World | $876M+4.0% | $889M-2.8% | $813M-1.6% | $933M+0.4% | $842M-4.2% | |
| U.S. | $5.6B+10.9% | $4.93B+5.5% | $5.88B+5.6% | $5.28B-3.1% | $5.05B+2.2% |
FAQ
- How does Gilead Sciences break its business down?
- Gilead Sciences (GILD) reports total revenues by product across 18 parts — AmBisome, Biktarvy, Descovy, Genvoya and Livdelzi. Each is extracted from the segment footnotes and tracked over time.
- Where does Gilead Sciences's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Gilead Sciences's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
